[go: up one dir, main page]

NO20025280D0 - Azabicykliske karbamater og deres anvendelse som alfa-7 nikotinisk acetylkolinreseptoragonister - Google Patents

Azabicykliske karbamater og deres anvendelse som alfa-7 nikotinisk acetylkolinreseptoragonister

Info

Publication number
NO20025280D0
NO20025280D0 NO20025280A NO20025280A NO20025280D0 NO 20025280 D0 NO20025280 D0 NO 20025280D0 NO 20025280 A NO20025280 A NO 20025280A NO 20025280 A NO20025280 A NO 20025280A NO 20025280 D0 NO20025280 D0 NO 20025280D0
Authority
NO
Norway
Prior art keywords
alpha
receptor agonists
acetylcholine receptor
nicotinic acetylcholine
azabicyclic
Prior art date
Application number
NO20025280A
Other languages
English (en)
Other versions
NO20025280L (no
Inventor
Joachim Nozulak
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20025280L publication Critical patent/NO20025280L/no
Publication of NO20025280D0 publication Critical patent/NO20025280D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20025280A 2000-05-05 2002-11-04 Azabicykliske karbamater og deres anvendelse som alfa-7 nikotinisk acetylkolinreseptoragonister NO20025280D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0010955.3A GB0010955D0 (en) 2000-05-05 2000-05-05 Organic compounds
PCT/EP2001/005008 WO2001085727A1 (en) 2000-05-05 2001-05-03 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists

Publications (2)

Publication Number Publication Date
NO20025280L NO20025280L (no) 2002-11-04
NO20025280D0 true NO20025280D0 (no) 2002-11-04

Family

ID=9891092

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025280A NO20025280D0 (no) 2000-05-05 2002-11-04 Azabicykliske karbamater og deres anvendelse som alfa-7 nikotinisk acetylkolinreseptoragonister

Country Status (29)

Country Link
US (1) US6780861B2 (no)
EP (1) EP1282620B1 (no)
JP (1) JP4898062B2 (no)
KR (1) KR20020093974A (no)
CN (1) CN1167703C (no)
AR (1) AR028073A1 (no)
AT (1) ATE263167T1 (no)
AU (2) AU2001262257B2 (no)
BR (1) BR0110521A (no)
CA (1) CA2407972C (no)
CZ (1) CZ20023622A3 (no)
DE (1) DE60102581T2 (no)
DK (1) DK1282620T3 (no)
ES (1) ES2218418T3 (no)
GB (1) GB0010955D0 (no)
HK (1) HK1054223B (no)
HU (1) HUP0301866A2 (no)
IL (1) IL152417A0 (no)
MX (1) MXPA02010892A (no)
NO (1) NO20025280D0 (no)
NZ (1) NZ522226A (no)
PE (1) PE20020221A1 (no)
PL (1) PL357435A1 (no)
PT (1) PT1282620E (no)
RU (1) RU2002131886A (no)
SK (1) SK15612002A3 (no)
TR (1) TR200401007T4 (no)
WO (1) WO2001085727A1 (no)
ZA (1) ZA200208969B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
US6740663B2 (en) * 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
EP1480977A2 (en) * 2002-02-15 2004-12-01 PHARMACIA & UPJOHN COMPANY Substituted aryl compounds for treatment of disease
WO2003070731A2 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
EE05516B1 (et) 2002-09-25 2012-02-15 Memory@Pharmaceuticals@Corporation Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
WO2004052365A2 (en) 2002-12-06 2004-06-24 North Shore-Long Island Jewish Research Institute Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
WO2004085433A2 (en) * 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
KR20060120694A (ko) * 2003-12-22 2006-11-27 메모리 파마슈티칼스 코포레이션 인돌, 1ｈ-인다졸, 1,2-벤즈이속사졸 및1,2-벤즈이소티아졸, 및 이들의 제법 및 용도
US20050170360A1 (en) * 2004-01-30 2005-08-04 Papke Roger L. Variant neuronal nicotinic alpha-7 receptor and methods of use
WO2005075479A1 (en) * 2004-02-04 2005-08-18 Neurosearch A/S Dimeric azacyclic compounds and their use
CA2560741C (en) 2004-03-25 2013-08-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
EP1742944B1 (en) * 2004-04-22 2010-11-10 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
EP1745046B1 (en) * 2004-05-07 2011-04-13 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benziosoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
ES2342675T3 (es) * 2004-12-22 2010-07-12 Memory Pharmaceuticals Corporation Ligandos del receptor alfa-7 nicotinico contra enfermedades relacionadas con el snc.
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
PE20110711A1 (es) 2008-11-19 2011-10-11 Envivo Pharmaceuticals Inc Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2429518A1 (en) * 2009-05-11 2012-03-21 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
JP2012533601A (ja) * 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
JP5633405B2 (ja) * 2010-02-18 2014-12-03 Jsr株式会社 新規化合物、感放射線性組成物及び硬化膜
CN102823159A (zh) * 2010-03-26 2012-12-12 康宁股份有限公司 低非线性长距离光传输系统
MX2012013345A (es) 2010-05-17 2013-02-11 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
CN103260619A (zh) 2010-07-26 2013-08-21 英维沃医药有限公司 利用某些α-7烟酸受体激动剂与乙酰胆碱酯酶抑制剂的组合治疗认知障碍
EP2667862A1 (en) * 2011-01-27 2013-12-04 Novartis AG Use of nicotinic acetylcholine receptor alpha 7 activators
HRP20200226T1 (hr) * 2011-03-18 2020-05-29 Genzyme Corporation Inhibitor glukozilceramid sintaze
US20140228398A1 (en) 2011-03-18 2014-08-14 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
CA2834467A1 (en) 2011-04-29 2012-11-01 Chiesi Farmaceutici S.P.A. Alkaloid ester and carbamate derivatives and medicinal compositions thereof
WO2013057687A2 (en) * 2011-10-20 2013-04-25 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
RU2635522C2 (ru) 2012-05-08 2017-11-13 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
JOP20130273B1 (ar) * 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
ES2661050T3 (es) 2012-12-11 2018-03-27 Novartis Ag Biomarcador predictivo de la capacidad de respuesta a tratamiento con activador del receptor nicotínico de acetilcolina alfa-7
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
CA2898043C (en) 2013-01-15 2019-08-06 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
MX378251B (es) 2013-01-15 2025-03-10 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
PL3920912T3 (pl) 2019-02-04 2025-11-12 Genzyme Corporation Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs)
BR112022014553A2 (pt) 2020-02-03 2022-09-20 Genzyme Corp Métodos para tratamento de sintomas neurológicos associados a doenças do armazenamento lisossômic
CA3186766A1 (en) 2020-07-24 2022-01-27 Danielle Combessis Pharmaceutical compositions comprising venglustat

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1996008468A1 (en) * 1994-09-14 1996-03-21 H. Lundbeck A/S Carbamoyloxy amine compounds
GB9525261D0 (en) 1995-12-11 1996-02-07 Bayer Ag Carbamic acid derivatives
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6313247B1 (en) * 1996-06-05 2001-11-06 Wolfgang Lindner Cinchonan based chiral selectors for separation of stereoisomers
US6525065B1 (en) * 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) * 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US5988429A (en) * 1997-10-14 1999-11-23 Pharmadesign, Inc. Blister pack pill dispenser
WO2001023383A1 (en) * 1999-09-28 2001-04-05 Eisai Co., Ltd. Quinuclidine compounds and drugs containing the same as the active ingredient
US6479510B2 (en) * 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
GB0109871D0 (en) * 2001-04-20 2001-06-13 Glaxo Group Ltd Metering method for particulate material

Also Published As

Publication number Publication date
EP1282620B1 (en) 2004-03-31
PT1282620E (pt) 2004-07-30
HUP0301866A2 (hu) 2003-09-29
AU6225701A (en) 2001-11-20
BR0110521A (pt) 2003-04-08
WO2001085727A1 (en) 2001-11-15
JP4898062B2 (ja) 2012-03-14
CN1427840A (zh) 2003-07-02
PE20020221A1 (es) 2002-04-23
HK1054223A1 (en) 2003-11-21
CA2407972A1 (en) 2001-11-15
EP1282620A1 (en) 2003-02-12
ES2218418T3 (es) 2004-11-16
HK1054223B (en) 2005-03-04
ZA200208969B (en) 2003-10-07
IL152417A0 (en) 2003-05-29
GB0010955D0 (en) 2000-06-28
DK1282620T3 (da) 2004-07-19
NZ522226A (en) 2004-08-27
PL357435A1 (en) 2004-07-26
AU2001262257B2 (en) 2004-11-04
TR200401007T4 (tr) 2004-07-21
MXPA02010892A (es) 2003-03-27
RU2002131886A (ru) 2004-04-10
SK15612002A3 (sk) 2003-04-01
JP2003532731A (ja) 2003-11-05
DE60102581T2 (de) 2005-02-03
AR028073A1 (es) 2003-04-23
DE60102581D1 (de) 2004-05-06
NO20025280L (no) 2002-11-04
CN1167703C (zh) 2004-09-22
CA2407972C (en) 2010-03-09
US6780861B2 (en) 2004-08-24
KR20020093974A (ko) 2002-12-16
US20030166654A1 (en) 2003-09-04
CZ20023622A3 (cs) 2003-02-12
ATE263167T1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
NO20025280L (no) Azabicykliske karbamater og deres anvendelse som alfa-7 nikotinisk acetylkolinreseptoragonister
DK1345937T3 (da) Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister
DK1200431T5 (da) Quinuclidinderivater og deres anvendelse som muskarine M3-receptorligander
NO20032277D0 (no) Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
NO990551D0 (no) Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
NO20021253D0 (no) Quinolyl propyl piperidinderivater og deres bruk som antibakterielle midler
NO20031619D0 (no) Substituerte indoler, farmasöytiske blandinger inneholdende slike indoler og deres anvendelse som PPAR-gamma-bindende midler
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
NO20000627D0 (no) ForhÕndsbelagte kontrollert - frigjørings - gjødningsmidler og fremgangsmÕter for deres fremstilling
DK1246802T3 (da) 4-aminopicolinater og deres anvendelse som herbicider
NO20030111D0 (no) Kjemokinreseptor-modulatorer, deres fremstilling og anvendelse
EP1657708A4 (en) SOUND INSULATION / ABSORPTION STRUCTURE AND STRUCTURE WITH THESE INSTALLED
NO20005146L (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20025640L (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptorantagonister
NO20015897D0 (no) Indolylpiperidinderivater som antihistaminiske og antiallergiske midler
NO20026103L (no) 1-amino-alkylcycloheksaner som 5-HT3 og neuronale nikotinreseptorantagonister
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
DK0880524T3 (da) Adenosinantagonister, fremgangsmåde til fremstilling deraf og deres anvendelse som medikamenter
NO20030547D0 (no) Azabicykliske derivater og deres terapeutiske anvendelse
NO20024105L (no) Memnopeptider, fremgangsmåte for deres fremstilling og anvendelse av disse
SI1282620T1 (en) Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
NO20022455D0 (no) Sulfonyloksazolaminer og deres anvendelse som 5-HT6- reseptorligander
NO20022457L (no) Substituerte 1,2,3,4,5,6-heksahydro-2,6-metano-3-benzazociner og deres anvendelse som medikamenter
DK1178045T3 (da) Azaindol-ethylaminderivater som nikotinacetylcholinreceptor-bindingsmidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application